|Dr. Geraldine A. Henwood Ph.D.||Chief Exec. Officer and Pres||933.38k||N/A||65|
|Mr. Michael Celano CPA||Chief Financial Officer||343.58k||N/A||58|
|Mr. Frederick H. Graff||Chief Commercial Officer||557.07k||N/A||67|
|Ms. Donna M. C. Nichols||Chief Accounting Officer, VP and Corp. Controller||N/A||N/A||61|
|Mr. Randall J. Mack||Sr. VP of Devel. and Corp. Sec.||N/A||N/A||52|
Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. Its lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. The company also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain. It also provides contract development and manufacturing services. It has a license agreement with Orion Corporation for the development and commercialization of Non-Injectable Dexmedetomidine. The company focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Recro Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.